SAB Biotherapeutics (SABS) president awarded 3,000,000 stock options

Rhea-AI Filing Summary

SAB Biotherapeutics reported that its president and director Eddie Joe Sullivan received a grant of stock options on 02/03/2026. The award covers 3,000,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan, as amended. These options vest over four years, with one quarter vesting on the first anniversary of the grant date and the remaining three quarters vesting in 36 equal monthly installments. Following this grant, Sullivan directly holds 3,000,000 derivative securities in the form of stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Eddie Joe

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.45	02/03/2026		A		3,000,000(1)		(2)	02/03/2036	Common Stock	3,000,000	$0	3,000,000	D

Explanation of Responses:

1. Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

2. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

	/s/ Eddie Sullivan	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SAB Biotherapeutics (SABS) report for Eddie Sullivan?

SAB Biotherapeutics reported that president and director Eddie Joe Sullivan received 3,000,000 stock options on February 3, 2026. These options allow him to buy common shares at $4.45, vesting over four years under the company’s 2021 Omnibus Equity Incentive Plan.

How many SAB Biotherapeutics stock options were granted to Eddie Sullivan and at what price?

Eddie Joe Sullivan was granted 3,000,000 SAB Biotherapeutics stock options with a $4.45 exercise price per share. The options were issued as a single grant and are tied to the company’s common stock with par value $0.0001 per share.

What is the vesting schedule for Eddie Sullivan’s 3,000,000 SAB Biotherapeutics options?

The 3,000,000 options vest over four years. One quarter vests on the one-year anniversary of the February 3, 2026 grant date, and the remaining three quarters vest in 36 equal monthly installments thereafter, aligning vesting with longer-term service at the company.

Under which equity plan were Eddie Sullivan’s SAB Biotherapeutics options granted?

The options were granted under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended. This plan authorizes equity-based awards such as stock options to company personnel, linking their potential upside to future performance of the common stock.

What is Eddie Sullivan’s ownership status after this SAB Biotherapeutics option grant?

After the grant, Eddie Joe Sullivan beneficially owns 3,000,000 derivative securities in the form of stock options directly. These options give him the right to purchase 3,000,000 shares of SAB Biotherapeutics common stock if and when they vest and are exercised.

What roles does Eddie Sullivan hold at SAB Biotherapeutics in this Form 4 filing?

In the Form 4, Eddie Joe Sullivan is identified as both a director and an officer of SAB Biotherapeutics, serving as president. The filing indicates the reported stock options are held directly in his name rather than through an indirect ownership vehicle.